Improving Drug Abuse Treatment by Research and Training

通过研究和培训改善药物滥用治疗

• 批准号: 6915475
• 负责人: Herbert David Kleber
• 金额: $ 12.29万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-07-01 至 2006-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6915475
• 关键词: Cannabis; buprenorphine; cocaine; detoxification; drug abuse chemotherapy; drug abuse therapy; drug withdrawal; heroin; human subject; human therapy evaluation; marijuana abuse; naltrexone; patient oriented research

DESCRIPTION: (Provided by Applicant) The overall aim of this K-05 proposal is to support and expand the applicant's work in developing and improving pharmacotherapy and psychotherapy for substance abuse as well as mentoring scientists embarking on such a career. The applicant has had a productive career in both areas, developing such programs first at Yale and currently at Columbia. During his eight years at Columbia the applicant has, in addition to these activities, served as Executive Vice President and Medical Director of CASA, a policy research center he and Joseph Califano founded in 1992. Receiving the K05 award would provide financial support for the candidate so that he could relinquish his CASA position with its administrative duties and policy research, and devote himself full time to biomedical research and training at the medical school. The applicant's current research has two major themes: 1) treating opioid withdrawal, 2) developing and improving medications and behavioral approaches for treating cocaine, heroin and marijuana dependence. Current funding for these areas is in hand for the first three years of this award. The applicant will direct a study comparing Anesthesia Rapid Opioid Detox (AROD) to Buprenorphine Rapid Opioid Detox to Clonidine Assisted Opioid Detox. The popularity of AROD has not been matched by evaluation of the technique, side effects and long term follow-up. This is the first controlled study to do so. In addition, the applicant will be PI at the Columbia site of a NIDA multi-site phase III trial of lofexidine, an alpha-adrenergic agonist with possible better efficacy than clonidine, and his Center will run an outpatient trial of a new Depot Naltrexone. Also focused on antagonist therapy is a Stage II Trial where he is Co-Investigator, testing a newly developed manualized psychotherapy for naltrexone-maintained individuals, which will also be the 1st study to test the usefulness of the new Depot Naltrexone in a clinical study. The Medication Development Research Center, where he is PI, focuses on targeting subgroups of addicts as well as development and/or utilization of models to improve testing potential medications. It includes human laboratory research on heroin, PET imaging, a large scale medication trial for cocaine, and testing potential medications for marijuana withdrawal and craving. In addition, the applicant plans to expand his time mentoring young scientists, including fellows on his training grant as well as young faculty. Additional time would also be spent in increasing collaborative research with other investigators at Columbia and developing new medication development projects.

描述：（由申请人提供）本 K-05 提案的总体目标是支持和扩展申请人的 致力于开发和改进药物治疗和心理治疗 药物滥用以及指导从事此类职业的科学家。这 申请人在这两个领域都取得了富有成效的职业生涯，开发了此类项目 首先在耶鲁大学，目前在哥伦比亚大学。在哥伦比亚大学的八年里 除了这些活动之外，申请人还担任过执行副总裁 他和 Joseph 是政策研究中心 CASA 的总裁兼医学主任 Califano 成立于 1992 年。获得 K05 奖项将提供财务支持 支持候选人，以便他可以放弃 CASA 职位 其行政职责和政策研究，并全力投入 医学院的生物医学研究和培训。 申请人目前的研究有两大主题：1）治疗阿片类药物 戒断，2）开发和改进药物和行为方法 用于治疗可卡因、海洛因和大麻依赖。目前的资金用于 这些领域是在该奖项的前三年内颁发的。申请人 将指导一项比较麻醉快速阿片类药物排毒 (AROD) 与 丁丙诺啡快速阿片类药物排毒可乐定辅助阿片类药物排毒。这 AROD 的受欢迎程度与该技术的评估不相匹配，侧面 效果和长期随访。这是第一个这样做的对照研究。 此外，申请人还将担任 NIDA 多站点哥伦比亚站点的 PI 洛非西定的 III 期试验，一种 α-肾上腺素能激动剂，可能具有更好的效果 疗效优于可乐定，他的中心将对一种新的药物进行门诊试验 仓库纳曲酮。同样关注拮抗剂治疗的是第二阶段试验，其中 他是联合研究员，正在测试一种新开发的手动心理疗法 纳曲酮维持的个体，这也将是第一项测试的研究 新的 Depot 纳曲酮在临床研究中的有用性。药物治疗 他是发展研究中心的 PI，重点关注以下子群体： 成瘾者以及开发和/或利用模型来改进测试 潜在的药物。它包括海洛因、PET 的人体实验室研究 成像、大规模可卡因药物试验以及测试潜力 用于大麻戒断和渴望的药物。此外，申请人 计划延长指导年轻科学家的时间，包括他的研究人员 培训补助金以及年轻教师。额外的时间也将花在 增加与哥伦比亚大学其他研究人员的合作研究 开发新药物开发项目。